Randomized clinical trials in unfavorable prognosis stage I-II Hodgkin's lymphoma.
| Group . | Treatment arms . | n . | FFS . | OS . | Time (y) . |
|---|---|---|---|---|---|
| Abbreviations: See Table 1; PAVe, procarbazine, melphalan (Alkeran), vinblastine; MF, mantle field; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; MOPP, nitrogen mustard, vincristine, procarbazine, prednisone; IFRT, involved field irradiation; ABV, doxorubicin, bleomycin, vinblastine | |||||
| Stanford | PAVe × 3 + MF + PAVe × 3 | 12 | 56% | 73% | 15 |
| ABVD × 3 + MF+ ABVD × 3 | 12 | 83% | 100% | ||
| p=0.1 | p=0.06 | ||||
| EORTC H6U | MOPP × 3 + MF + MOPP × 3 | 165 | 77% | 87% | 10 |
| ABVD × 3 + MF +ABVD × 3 | 151 | 88% | 87% | ||
| p<0.01 | p=0.52 | ||||
| EORTC H7U | EBVP × 6 + IFRT 36 Gy | 160 | 68% | 82% | 6 |
| MOPP/ABV × 6 + IFRT 36 Gy | 156 | 90% | 89% | ||
| p<0.0001 | p=0.18 | ||||
| Group . | Treatment arms . | n . | FFS . | OS . | Time (y) . |
|---|---|---|---|---|---|
| Abbreviations: See Table 1; PAVe, procarbazine, melphalan (Alkeran), vinblastine; MF, mantle field; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; MOPP, nitrogen mustard, vincristine, procarbazine, prednisone; IFRT, involved field irradiation; ABV, doxorubicin, bleomycin, vinblastine | |||||
| Stanford | PAVe × 3 + MF + PAVe × 3 | 12 | 56% | 73% | 15 |
| ABVD × 3 + MF+ ABVD × 3 | 12 | 83% | 100% | ||
| p=0.1 | p=0.06 | ||||
| EORTC H6U | MOPP × 3 + MF + MOPP × 3 | 165 | 77% | 87% | 10 |
| ABVD × 3 + MF +ABVD × 3 | 151 | 88% | 87% | ||
| p<0.01 | p=0.52 | ||||
| EORTC H7U | EBVP × 6 + IFRT 36 Gy | 160 | 68% | 82% | 6 |
| MOPP/ABV × 6 + IFRT 36 Gy | 156 | 90% | 89% | ||
| p<0.0001 | p=0.18 | ||||